Safety and efficacy of nusinersen and risdiplam for spinal muscular atrophy: a systematic review and meta-analysis of randomized controlled trials. | 2023 | Brain Sciences |
Adverse events in the treatment of spinal muscular atrophy in children and adolescents with nusinersen: a systematic review and meta-analysis. | 2022 | Frontiers in Pediatrics |
Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: a systematic review of real-world study data | 2022 | European Journal of Paediatric Neurology |
Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: a systematic review of real-world study data. | 2022 | Medicina |
Nusinersen in adults with 5q spinal muscular atrophy: a systematic review and meta-analysis. | 2022 | Neurotherapeutics |
How does risdiplam compare with other treatments for types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison. | 2022 | Journal of Comparative Effectiveness Research |
Motor function in type 2 and 3 SMA patients treated with nusinersen: a critical review and meta-analysis. | 2021 | Orphanet Journal of Rare Diseases |
Nusinersen treatment of spinal muscular atrophy - a systematic review. | 2020 | Danish Medical Journal |
Drug treatment for spinal muscular atrophy types II and III. | 2020 | The Cochrane Database of Systematic Reviews |
Drug treatment for spinal muscular atrophy type I. | 2019 | The Cochrane Database of Systematic Reviews |